Montelukast Eurogenerics

Montelukast, the active ingredient in Montelukast Eurogenerics, is a leukotriene receptor antagonist presented as a tablet for oral use. It treats asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Eurogenerics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and bronchoconstriction. - Asthma: improves control of persistent asthma and reduces exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing and itching caused by seasonal allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nausea: occasional upset stomach. - Dizziness: brief episodes. - Upper respiratory infection: mild symptoms.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or tongue. - Liver injury: elevated transaminases. - Mood changes: depression or suicidal thoughts. - Allergic reactions: rash, pruritus, urticaria. - Stevens‑Johnson syndrome: severe skin eruption. - Eosinophilic pneumonia: respiratory distress with eosinophil accumulation.

Montelukast should be used with awareness of specific safety considerations. - Pregnancy: consult a healthcare provider as safety category is unknown. - Breastfeeding: caution because the drug is excreted in milk. - Pediatric use: approved for children according to label specifications. - Drug interactions: review all concomitant medicines for potential effects. - Renal/hepatic impairment: consider dose adjustment or monitoring. - Store at room temperature: keep in the original container, protect from moisture and light.

Montelukast may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Ritonavir: may increase montelukast plasma concentrations. - Phenobarbital: may reduce montelukast effectiveness. - Carbamazepine: may lower drug exposure.

Moderate Interactions (Monitor Closely): - Fluconazole: may raise montelukast levels. - Warfarin: monitor INR for possible changes. - β‑agonists: additive bronchodilator effects may occur.